Japan’s ruling coalition sustained a crushing blow in the Lower House election last month, only managing to win 215 seats,…
HOME > BUSINESS
BUSINESS
- Gilead Completes Marketing Authorization Transfer for Yescarta in Japan
June 23, 2023
- Astellas Chairman Snags 452 Million Yen in FY2022: Securities Report
June 23, 2023
- Combined Sales of 26 Japan Drug Makers Up 13.6% in FY2022 on Global Growth, COVID Demand
June 22, 2023
- Nippon Shinyaku Files Jazz’s High-Risk AML Drug in Japan
June 22, 2023
- 4 Eisai Execs Earn 100 Million Yen-Plus Pay, CEO Takes Home 157 Million Yen
June 22, 2023
- Global Pharma Market Grows 8.3% in 2022, Humira Top-Seller Drug: IQVIA
June 21, 2023
- ASKA Seeks Pediatric Indication for Rifxima in Japan
June 21, 2023
- Wegovy Rollout Being Delayed due to Unprecedented Demand: Novo Japan Chief
June 21, 2023
- Daiichi Sankyo Chair Snares 402 Million Yen in FY2022: Securities Report
June 20, 2023
- Entyvio SC Now Available in Japan: Takeda
June 20, 2023
- Mitsubishi Tanabe VC Firm Certified for AMED Startup Project
June 19, 2023
- Hutchmed’s Colorectal Cancer Med Accepted for European Review: Takeda
June 19, 2023
- As Wholesalers Try to Negotiate Higher Prices, Hospitals Face Tougher Haggling This Year
June 16, 2023
- PharmaEssentia Eyes Japan Sales of 50 Billion Yen in 2030
June 16, 2023
- Astellas Inks Protein Degrader Deal with Cullgen
June 16, 2023
- Opdivo Filed for Malignant Epithelial Tumors in Japan
June 16, 2023
- Azilva, Allermist Authorized Generics to Hit Japan Market on June 16
June 16, 2023
- Japan Regenerative Drug Market to Reach 72.3 Billion Yen in 2030: Fuji Keizai
June 16, 2023
- Ohara’s Cancer Med Erwinase Reaches Japan Market Over 6 Years after Approval
June 15, 2023
- Chugai Files NDA for PNH Drug Crovalimab in Japan
June 15, 2023
ページ
For over two decades, Morunda has been at the forefront of interviewing and understanding leaders within Japan’s dynamic healthcare industry, particularly in pharmaceuticals and medical devices. What sets apart successful country managers in this competitive arena isn’t just their professional…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…